ECDC expert opinion on efficacy and effectiveness of neuraminidase inhibitors published for public consultation.
作者信息
Penttinen Pasi, Catchpole Mike
出版信息
Influenza Other Respir Viruses. 2016 May;10(3):152-3. doi: 10.1111/irv.12377.
Abstract
摘要
相似文献
1
ECDC expert opinion on efficacy and effectiveness of neuraminidase inhibitors published for public consultation.
Influenza Other Respir Viruses. 2016 May;10(3):152-3. doi: 10.1111/irv.12377.
2
ECDC public consultation on the use of neuraminidase inhibitors.
Euro Surveill. 2016;21(7):pii=30140.
3
[Controversies about neuraminidase inhibitor. Is the influenza drug less effective than assumed?].
MMW Fortschr Med. 2010 Jan 21;152(3):7. doi: 10.1007/BF03365908.
4
Neuraminidase inhibitors for influenza.
BMJ. 2014 Apr 9;348:g2548. doi: 10.1136/bmj.g2548.
5
Effectiveness of neuraminidase inhibitors for severe influenza.
Lancet Respir Med. 2014 May;2(5):346-8. doi: 10.1016/S2213-2600(14)70068-2. Epub 2014 Mar 19.
6
Should neuraminidase inhibitors be prescribed for patients with influenza?
Ann Emerg Med. 2014 Jan;63(1):54-5. doi: 10.1016/j.annemergmed.2013.07.495. Epub 2013 Aug 7.
7
Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children.
Sao Paulo Med J. 2014;132(4):256-7. doi: 10.1590/1516-3180.20141324t2.
8
Antiviral medications for influenza.
Can Fam Physician. 2015 Apr;61(4):351.
9
Neuraminidase inhibitors for preventing and treating influenza in children (published trials only).
Cochrane Database Syst Rev. 2012 Apr 18;2012(4):CD002744. doi: 10.1002/14651858.CD002744.pub4.
10
Neuraminidase inhibitors for treatment and prophylaxis of influenza in children: systematic review and meta-analysis of randomised controlled trials.
BMJ. 2009 Aug 10;339:b3172. doi: 10.1136/bmj.b3172.
引用本文的文献
1
Containing influenza outbreaks with antiviral use in long-term care facilities in Taiwan, 2008-2014.
Influenza Other Respir Viruses. 2018 Mar;12(2):287-292. doi: 10.1111/irv.12536. Epub 2018 Jan 28.
2
Influenza in long-term care facilities.
Influenza Other Respir Viruses. 2017 Sep;11(5):356-366. doi: 10.1111/irv.12464. Epub 2017 Jul 26.
3
Japanese Surveillance Systems and Treatment for Influenza.
Curr Treat Options Infect Dis. 2016;8(4):311-328. doi: 10.1007/s40506-016-0085-5. Epub 2016 Oct 10.
本文引用的文献
1
Influenza: the rational use of oseltamivir.
Lancet. 2015 May 2;385(9979):1700-1702. doi: 10.1016/S0140-6736(15)60074-5. Epub 2015 Jan 30.
2
Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials.
Lancet. 2015 May 2;385(9979):1729-1737. doi: 10.1016/S0140-6736(14)62449-1. Epub 2015 Jan 30.
3
Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data.
Lancet Respir Med. 2014 May;2(5):395-404. doi: 10.1016/S2213-2600(14)70041-4. Epub 2014 Mar 19.
4
The Tamiflu trials.
BMJ. 2014 Apr 9;348:g2630. doi: 10.1136/bmj.g2630.
5
Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments.
BMJ. 2014 Apr 9;348:g2547. doi: 10.1136/bmj.g2547.
6
Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments.
BMJ. 2014 Apr 9;348:g2545. doi: 10.1136/bmj.g2545.
7
Neuraminidase inhibitors for preventing and treating influenza in adults and children.
Cochrane Database Syst Rev. 2014 Apr 10;2014(4):CD008965. doi: 10.1002/14651858.CD008965.pub4.
8
2009 pandemic influenza A (H1N1) in pregnancy: a systematic review of the literature.
Am J Obstet Gynecol. 2011 Jul;205(1):10-8. doi: 10.1016/j.ajog.2010.12.033. Epub 2011 Feb 23.
9
Use of oseltamivir after influenza infection is associated with reduced incidence of recurrent adverse cardiovascular outcomes among military health system beneficiaries with prior cardiovascular diseases.
Circ Cardiovasc Qual Outcomes. 2009 Mar;2(2):108-15. doi: 10.1161/CIRCOUTCOMES.108.820357. Epub 2009 Mar 5.
Zotero 插件